六味五灵片联合恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者的疗效观察  

Clinical observation on influence of Liuweiwuling tablets combined with entecavir on chronic hepatitis B patients with HBeAg positive

作　　者：高爱华[1] 王新丽[1] 姜清河 张凤朝[1] 

机构地区：[1]沧州市传染病医院,沧州市061001

出　　处：《中国肝脏病杂志（电子版）》2011年第1期35-37,共3页Chinese Journal of Liver Diseases：Electronic Version

摘　　要：目的探讨恩替卡韦(ETV)联合六味五灵片治疗HBeAg阳性慢性乙型肝炎(CHB)患者的疗效。方法 102例HBeAg阳性CHB患者随机分为两组,联合治疗组50例每日服用ETV0.5mg,六味五灵片1.5g,每日3次;对照组52例每日服用ETV0.5mg。分别观察服药第12、24、52周时肝肾功能、血清HBeAg及HBV DNA水平。结果治疗52周结束时联合治疗组和对照组ALT复常率分别为88%和69.23%(P<0.01);HBeAg/HBeAb血清学转换率分别为34%和25%(P<0.05)。结论联合治疗组在ALT复常及HBeAg/HBeAb血清学转换方面均优于对照组,六味五灵片联合恩替卡韦可以起到很好的协同抗病毒的作用。Objective To observe the clinical effects of Liuweiwuling tablets in combination with entecavir（ETV） on chronic hepatitis B patients with HBeAg positive.Methods Total of 102 chronic hepatitis B patients with HBeAg positive were randomly divided into treatment group and control group：the control group were treated with ETV（0.5 mg/d） for 52 weeks;while the treatment group were treated with Liuweiwuling tablets,besides the ETV（0.5 mg/d） therapy for 52 weeks.The liver and kidney function,serum HBeAg and HBV DNA were observed at the 12,24,52 weeks.Results The ALT recovery rate of treatment group and control group were 88%,69.23% at 52 weeks respectively,there were signif icant statistical differences between the two groups（P 0.01）;the seroconversion rate of HBeAg/HBeAb are 34%,25%,respectively（P 0.05）.Conclusions The liver function index and the seroconversion rate of HBeAg/HBeAb in treatment group are better than control group,Liuweiwuling tablets in combination with ETV has a great cooperative effect on inhibiting hepatitis B virus for chronic hepatitis B patients with HBeAg positive.

关 键 词：肝炎 乙型 慢性 六味五灵片 恩替卡韦 

分 类 号：R512.62[医药卫生—内科学]